FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2592162340> ?p ?o ?g. }

• W2592162340 endingPage "968" @default.
• W2592162340 startingPage "960" @default.
• W2592162340 abstract "Abstract Background OnabotulinumtoxinA is approved for the treatment of upper and lower limb spasticity in adults. Guidance on common postures and onabotulinumtoxinA injection paradigms for upper limb spasticity has been developed via a Delphi Panel; however, similar guidance for lower limb spasticity has not been established. Objective To define a clinically recommended treatment paradigm for the use of onabotulinumtoxinA for each common posture among patients with poststroke lower limb spasticity (PSLLS) and to identify the most common PSLLS aggregate postures. Design Clinical experts provided insight regarding onabotulinumtoxinA treatment for PSLLS using an adaptation of the Delphi consensus process. Setting Delphi panel. Participants Ten expert clinicians in neurology and physical medicine and rehabilitation who treat PSLLS. Methods A minimum of 2 rounds of anonymous voting occurred for each recommendation until consensus was reached (≥66% agreement). The first round was conducted via a survey; the second round was an in‐person meeting. Main Outcome Measurements Reached consensus on muscle selection for injection, overall and per‐muscle dose of onabotulinumtoxinA, number of injection sites/muscle, onabotulinumtoxinA dilution, and use of localization techniques. The most common PSLLS postures were reviewed. Recommendations were tailored toward injectors with less experience. Results Consensus was reached on targeted subsets of muscles for each posture. Doses ranged from 20 to 150 U for individual muscles and 50 to 300 U for limb postures. OnabotulinumtoxinA dilution 50 U/mL (2:1 ratio) was considered most appropriate but varied based on muscles selected (range, 2:1‐4:1). Experts agreed that localization techniques for muscle identification during injection for all postures would be useful. For suboptimal response to injection, all panel members would increase the dose, and the majority (89%) would increase the number of treated muscles. The panel identified 3 common aggregating lower limb postures: (1) equinovarus foot and flexed toes; (2) extended knee and plantar flexed foot/ankle; and (3) plantar flexed foot/ankle and flexed toes. The recommended starting doses for each aggregate posture were 400 U, 400 U, and 300 U, respectively. Conclusion The modified Delphi panel process provided consensus on common muscles and corresponding onabotulinumtoxinA treatment paradigms for postures associated with PSLLS that can be used for guidance in optimizing care delivery. Level of Evidence V" @default.
• W2592162340 created "2017-03-16" @default.
• W2592162340 creator A5014686861 @default.
• W2592162340 creator A5025229446 @default.
• W2592162340 creator A5027510501 @default.
• W2592162340 creator A5028940776 @default.
• W2592162340 creator A5045469742 @default.
• W2592162340 creator A5050673414 @default.
• W2592162340 creator A5068850091 @default.
• W2592162340 creator A5072827067 @default.
• W2592162340 creator A5074794910 @default.
• W2592162340 creator A5078499716 @default.
• W2592162340 date "2017-03-07" @default.
• W2592162340 modified "2023-09-29" @default.
• W2592162340 title "OnabotulinumtoxinA for Lower Limb Spasticity: Guidance From a Delphi Panel Approach" @default.
• W2592162340 cites W1968468300 @default.
• W2592162340 cites W1975521953 @default.
• W2592162340 cites W1976314774 @default.
• W2592162340 cites W1982352761 @default.
• W2592162340 cites W1990705912 @default.
• W2592162340 cites W2001717138 @default.
• W2592162340 cites W2003041870 @default.
• W2592162340 cites W2003673175 @default.
• W2592162340 cites W2009066073 @default.
• W2592162340 cites W2014820798 @default.
• W2592162340 cites W2028433923 @default.
• W2592162340 cites W2032606733 @default.
• W2592162340 cites W2035831598 @default.
• W2592162340 cites W2038547978 @default.
• W2592162340 cites W2046697585 @default.
• W2592162340 cites W2060531015 @default.
• W2592162340 cites W2061136806 @default.
• W2592162340 cites W2078724959 @default.
• W2592162340 cites W2101873925 @default.
• W2592162340 cites W2103663511 @default.
• W2592162340 cites W2110303328 @default.
• W2592162340 cites W2120460040 @default.
• W2592162340 cites W2144383590 @default.
• W2592162340 cites W2145077102 @default.
• W2592162340 cites W2165447041 @default.
• W2592162340 cites W2468551644 @default.
• W2592162340 cites W4231953711 @default.
• W2592162340 doi "https://doi.org/10.1016/j.pmrj.2017.02.014" @default.
• W2592162340 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28286053" @default.
• W2592162340 hasPublicationYear "2017" @default.
• W2592162340 type Work @default.
• W2592162340 sameAs 2592162340 @default.
• W2592162340 citedByCount "29" @default.
• W2592162340 countsByYear W25921623402017 @default.
• W2592162340 countsByYear W25921623402018 @default.
• W2592162340 countsByYear W25921623402019 @default.
• W2592162340 countsByYear W25921623402020 @default.
• W2592162340 countsByYear W25921623402021 @default.
• W2592162340 countsByYear W25921623402022 @default.
• W2592162340 countsByYear W25921623402023 @default.
• W2592162340 crossrefType "journal-article" @default.
• W2592162340 hasAuthorship W2592162340A5014686861 @default.
• W2592162340 hasAuthorship W2592162340A5025229446 @default.
• W2592162340 hasAuthorship W2592162340A5027510501 @default.
• W2592162340 hasAuthorship W2592162340A5028940776 @default.
• W2592162340 hasAuthorship W2592162340A5045469742 @default.
• W2592162340 hasAuthorship W2592162340A5050673414 @default.
• W2592162340 hasAuthorship W2592162340A5068850091 @default.
• W2592162340 hasAuthorship W2592162340A5072827067 @default.
• W2592162340 hasAuthorship W2592162340A5074794910 @default.
• W2592162340 hasAuthorship W2592162340A5078499716 @default.
• W2592162340 hasBestOaLocation W25921623401 @default.
• W2592162340 hasConcept C111919701 @default.
• W2592162340 hasConcept C118552586 @default.
• W2592162340 hasConcept C154945302 @default.
• W2592162340 hasConcept C16568411 @default.
• W2592162340 hasConcept C1862650 @default.
• W2592162340 hasConcept C2776660947 @default.
• W2592162340 hasConcept C2778818304 @default.
• W2592162340 hasConcept C2779012798 @default.
• W2592162340 hasConcept C2779495148 @default.
• W2592162340 hasConcept C41008148 @default.
• W2592162340 hasConcept C60641444 @default.
• W2592162340 hasConcept C71924100 @default.
• W2592162340 hasConcept C99508421 @default.
• W2592162340 hasConceptScore W2592162340C111919701 @default.
• W2592162340 hasConceptScore W2592162340C118552586 @default.
• W2592162340 hasConceptScore W2592162340C154945302 @default.
• W2592162340 hasConceptScore W2592162340C16568411 @default.
• W2592162340 hasConceptScore W2592162340C1862650 @default.
• W2592162340 hasConceptScore W2592162340C2776660947 @default.
• W2592162340 hasConceptScore W2592162340C2778818304 @default.
• W2592162340 hasConceptScore W2592162340C2779012798 @default.
• W2592162340 hasConceptScore W2592162340C2779495148 @default.
• W2592162340 hasConceptScore W2592162340C41008148 @default.
• W2592162340 hasConceptScore W2592162340C60641444 @default.
• W2592162340 hasConceptScore W2592162340C71924100 @default.
• W2592162340 hasConceptScore W2592162340C99508421 @default.
• W2592162340 hasFunder F4320332585 @default.
• W2592162340 hasIssue "10" @default.
• W2592162340 hasLocation W25921623401 @default.
• W2592162340 hasLocation W25921623402 @default.
• W2592162340 hasOpenAccess W2592162340 @default.

• next